ClinicalTrials.gg
CompletedNCT05925725Updated Nov 15, 2023

Clinical Efficacy and Safety of Loxacon Dietary Supplement Capsules at Patients With Knee Arthrosis

A Phase 4 interventional study of • harpagozid • boswellin = LOXACON in Osteo Arthritis Knee, sponsored by Polyclinic of the Hospitaller Brothers of St. John of God, Budapest. Completed at 1 site in Hungary. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-11-15.

Sponsored by Polyclinic of the Hospitaller Brothers of St. John of God, Budapest · Phase 4, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Study summary

The study will be a multicenter, randomized, double-blind, follow-up clinical trial.

Neither the examining doctor nor the patient knows which capsule they will receive. Just the test unlock the codes after completion. T

Read the detailed description

The study will be a multicenter, randomized, double-blind, follow-up clinical trial.

Neither the examining doctor nor the patient knows which capsule they will receive. Just the test unlock the codes after completion. The randomization was performed externally, not included in the study performed by a person. Number of patients: a total of 105 patients / 25-25 per clinic (with 8 patients each in three treatment groups) Three treatment groups

  • 35 people physical therapy + Loxacon
  • 35 main physical therapy + Placebo
  • 35 people only for physical therapy Physiotherapy(exercise) takes place according to a uniform protocol. Physiotherapy 2x30 minutes per week for 5 weeks (10 times in total). The course of the investigation

    1. st visit: selection, filling in questionnaires
    2. nd visit: after the 10th exercise session, while taking Loxacon/placebo, filling in questionnaires
    3. rd visit: Uniformly after another 2 months of taking Loxacon, in all three groups, completing questionnaires After the first 5 weeks, all three branches will receive enough Loxacon capsules for 2 months! The parameters to be tested

      • WOMAC test
      • VAS
      • EQ-5D-5L quality of life test
      • Goniometer angle measurement The test is completed by patients who participated in more than 70% of the treatment! Monitoring of side effects It is the duty of the doctor of the given center - who reports to the investigator.
02

Conditions studied

  • Osteo Arthritis Knee

Keywords

  • Boswellia serrata,
  • Harpagophytum procumbens,
  • knee OA
03

In context

Lead sponsor

Polyclinic of the Hospitaller Brothers of St. John of God, Budapest is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria Must be able to swallow tablets

  • According to the ACR (American College of Rheumatology) knee arthrosis criteria, knee arthrosis supported by an imaging procedure (comparative knee X-ray). Both in the case of knee involvement, the more complaining knee will be examined! 2. A patient reporting knee pain characteristic of knee arthrosis for at least 3 months, where the VAS value 40-70 mm. 3. With a diagnosis of mild and moderate knee arthrosis. 4. Male or female patients between the ages of 40 and 80. 5. With a BodyMassIndex between 25-35.

Exclusion Criteria:EXCLUSION CRITERIA

  • Intra-articular within 3 months before starting treatment injection.
  • Intra-articular hyaluronic acid treatment within 6 months or such treatment during the examination treatment.
  • Physiotherapy treatment received within 3 months prior to the start of the treatment.
  • NSAID changed within 3 months prior to treatment or during treatment, or chondroprotective treatment.
  • In inflammatory rheumatological diseases (RA, SPA, APs, crystal arthropathies, etc.) suffering patient.
  • Knee surgery within 6 months prior to the examination.
  • Presence of a metal implant in the knee joint.
  • Patients who had a knee joint injury within 6 months prior to the examination.
  • Patients with a palpable fluid collection in the knee or Baker's cyst.
  • Uncooperative patients, patients with inadequate mental or psychological status.

Clinical diagnosis of Alzheimer's Disease

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Active comparator
    Loxacon and Physical Therapy

    physical therapy(exercise) + caps Loxacon

    Drug: • harpagozid • boswellin = LOXACON

  • Placebo comparator
    Physical therapy and Placebo Loxacon caps

    Physical therapy + Placebo caps Loxacon

    Drug: • harpagozid • boswellin = LOXACON

  • Active comparator
    Pphysical therapy(alone)

    Physical therapy

    Drug: • harpagozid • boswellin = LOXACON

Interventions

  • Drug• harpagozid • boswellin = LOXACON

    Exercise therapy

    Also known as: Physiotherapy(exercise)

06

What researchers measure

Primary outcomes

  1. Western Ontario and McMaster Universities Arthritis Index (WOMAC)

    The test questions are scored on a scale of 0-4, whichcorrespondto: None (0), Mild (1) , Moderate (2), Severe (3), and Extreme (4).

    Time frame: one year

  2. Visual analog The Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be')

    pain measurement The higher score the worser

    Time frame: "through study completion, an average of 1 year".

  3. GONIOMETER

    Range of motion(0-140)Goniometry is the art and science of measuring the joint ranges in each plane of the joint.The hihger the movements's degree the better the result of exercise

    Time frame: "through study completion, an average of 1 year".

  4. Knee Injury and Osteoarthritis Outcome Score (KOOS)

    The KOOS evaluates both short-term and long-term consequences of knee injury. It holds 42 items in 5 separately scored subscales; Pain, otherSymptoms, Function in dailyliving (ADL), Function in Sport and Recreation (Sport/Rec), and knee-relatedQuality of Life (QOL)KOOS consists of 5 subscales; long-term patient-relevant outcomes following knee injury

    Time frame: "through study completion, an average of 1 year".

Secondary outcomes

  1. Euroquol Group index EQ-5D-he EQ-5D

    is a commonly used general questionnaire belonging to the first group. When filling it out, respondents in 5 dimensions: mobility, self-sufficiency, usual activities, pain/discomfort, anxiety/depression; They can choose from 3 levels (1: least, 3: most).

    Time frame: "through study completion, an average of 1 year".

07

Study locations

1 site
  • Lakitelek foundation
    Lakitelek, Hungary
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in May 2023, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2023
First posted
Jun 29, 2023
StartActual
Jan 25, 2023
Primary completionActual
May 5, 2023
CompletionActual
Sep 6, 2023
Last update
Nov 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05925725
Lead sponsor
Polyclinic of the Hospitaller Brothers of St. John of God, Budapest
Responsible party
Tamas Bender (professor of Medicine, Polyclinic of the Hospitaller Brothers of St. John of God, Budapest) — Principal investigator
First posted
Jun 29, 2023
Start date
Jan 25, 2023
Primary completion
May 5, 2023
Completion
Sep 6, 2023
Last update
Nov 15, 2023

Study contacts

Zoltán Dégi, M.D
study director · Goodwill Pharma
Zoltán Dégi
study chair · Goodwill Pharma
Tamas Bender
principal investigator · Polyclinic of the Hospitaller Brothers of St. John of God, Budapest

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion